
    
      This is a combined phase 1 and 2 clinical study. The study is to assess the safety and
      efficacy of the anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells for patients
      with advanced non-small cell lung cancer. The treatment outcomes will be compared.
    
  